Reference
Medicines and Healthcare products Regulatory Agency. Brolucizumab (Beovu): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals Drug Safety Update 15: No. 6, Jan 2022. Available from: URL: https://www.gov.uk/drug-safety-update/brolucizumab-beovuv-risk-of-intraocular-inflammation-and-retinal-vascular-occlusion-increased-with-short-dosing-intervals
Rights and permissions
About this article
Cite this article
Dosing intervals affect risk of brolucizumab-related retinal disorders. Reactions Weekly 1892, 2 (2022). https://doi.org/10.1007/s40278-022-09544-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-09544-2